Navigation Links
A new 'bent' on fusion
Date:8/20/2009

theory had never been tested. That study used vesicles that already were highly curved, so it was not clear what bending effect synaptotagmin was actually having on them.

The Chapman team addressed the problem by creating vesicles with different degrees of curvature, including some that were only slightly curved. By exposing the differently curved vesicles to mutated synaptotagmin, which lacked membrane-bending capability, the researchers showed that the target membrane must be bent for fusion to occur.

To find a way to compensate for the mutated synaptotagmin's inability to bend membranes, Chapman's group turned to a protein that controls the bending of membranes when vesicles are returned to their original form during fission, which involves the splitting apart of membranes in a process called endocytosis. The researchers found that the endocytic protein overcame the fusion deficiency.

"Nobody had ever done this," notes Chapman, "although L.V. Chernomordik had suggested that fission and fusion proceed via similar intermediate structures. He was right."


'/>"/>

Contact: Dian Land
dj.land@hosp.wisc.edu
608-261-1034
University of Wisconsin-Madison
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. How mitochondria get their membranes bent
2. Newly discovered gene fusion may lead to improved prostate cancer diagnosis
3. UC Davis bioengineer receives Hartwell Foundation grant to address skull fusion disorder of infants
4. Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes
5. A simple fusion to jump-start evolution
6. New book includes advances in the science and practice of transfusion and transplantation
7. Singapore opens Fusionopolis, its second major R&D hub in 5 years
8. Researchers tap into a new and potentially better source of platelets for transfusion
9. Inflammation triggers cell fusions that could protect neurons, Stanford research shows
10. Singapores BIOPOLIS and FUSIONOPOLIS on stage in Boston this week
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2More than fish bait: Worms unlock secrets to new epilepsy treatments 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4PDL BioPharma to Present at Oppenheimer 26amp 3B Co 20th Annual Healthcare Conference on November 4 2009 14619 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 2Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 3Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 4Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 5Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 6Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 7Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 1Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 2Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 3Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 4Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 5Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 6Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 7Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 9Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 10Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 11Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 12Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 13Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 14Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 15Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 16Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 17Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 18Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 19Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 20Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 21Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 22